A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
Public ClinicalTrials.gov record NCT03143153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
Study identification
- NCT ID
- NCT03143153
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 970 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin Drug
- Fluorouracil Drug
- Ipilimumab Biological
- Nivolumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2017
- Primary completion
- Jan 17, 2021
- Completion
- Jan 12, 2025
- Last update posted
- Feb 16, 2026
2017 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0191 | Mobile | Alabama | 36608 | — |
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Usc/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Local Institution - 0188 | Denver | Colorado | 80218 | — |
| University Of Miami Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Local Institution - 0186 | Miami | Florida | 33176 | — |
| Local Institution - 0225 | Tampa | Florida | 33612 | — |
| Local Institution - 0074 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0032 | Marietta | Georgia | 30060 | — |
| Hackensack Meridian Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | — |
| Oncology Associates Of Oregon, Pc | Eugene | Oregon | 97401 | — |
| Northwest Cancer Specialists, P.C. | Portland | Oregon | 97227 | — |
| Local Institution - 0210 | Dallas | Texas | 75246 | — |
| Local Institution - 0028 | Houston | Texas | 77030 | — |
| Local Institution - 0190 | Roanoke | Virginia | 24014 | — |
| Local Institution - 0203 | Morgantown | West Virginia | 26506-9162 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 174 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03143153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03143153 live on ClinicalTrials.gov.